Form D · Biotechnology
Cardiff Oncology, Inc.
San Diego, CA · CIK 0001213037
Offering snapshot reported Jun 23, 2020 · SEC filing
- Reported sold
- $13.5M Offering amount: $13.5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 16, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 23, 2020 | Initial | $13,500,000 | No comparison | 3 | SEC filing |
| Jun 1, 2020 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| May 21, 2020 | Initial | $810,000 | No comparison | 8 | SEC filing |
| Apr 14, 2020 | Initial | $2,084,000 | No comparison | 1 | SEC filing |
| Oct 30, 2019 | Initial | $5,000,000 | No comparison | 2 | SEC filing |
| Aug 28, 2019 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| May 20, 2019 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Apr 10, 2019 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Jul 24, 2017 | Initial | $0 | No comparison | 4 | SEC filing |
| Dec 7, 2012 | Initial | $3,760,000 | No comparison | 8 | SEC filing |
| Mar 26, 2012 | Initial | $6,598,200 | No comparison | 40 | SEC filing |
| Feb 19, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 22, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 28, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 9, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-369462
Source: Form D, filed Jun 23, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Adams | Director |
| Thomas Adams, Ph.D. | Director |
| James O. Armitage | Director |
| Paul Billings | Director |
| John Brancaccio | Director |
| Gabriele Cerrone | Director |
| Athena Countouriotis | Director |
| Mark Erlander | Director, Executive |
| Mark Erlander, Ph.D. | Executive |
| Gary Jacob | Director |
| Gary Jacob, Ph.D. | Director |
| Brigitte Lindsay | Executive |
| Rodney S. Markin | Director |
| Gary W. Pace | Director |
| Gary Pace, Ph.D. | Director |
| David Robbins | Executive |
| Antonius Schuh | Director, Executive |
| Stanley Tennant | Director |
| William Welch | Director, Executive |
| Lale White | Director |
| Steve Zanibobi | Executive |
| Steve Zaniboni | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11055 Flintkote Avenue
San Diego, CA, 92121
San Diego, CA, 92121